Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Earnings Call

Cerus Earnings Call: Key Takeaways

Cerus delivered 10% revenue growth and positive Phase III Redis results, though regulatory timelines for the INT200 and CE Mark red cells have shifted later.

Full earnings call on the Alfa Finder USA YouTube channel · Open on YouTube ↗
Highlights
Revenue GrowthNorth America up 12%; EMEA up 5%; IFC revenue $5.6M vs $3.9M.
Mgmt ConfidenceHigh confidence in long-term mission despite transient geopolitical and FX headwinds.
Demand VisibilityStrong momentum in BCA member centers; international illuminator placements exceeding expectations.
Margin TrendsGross margin 52.4% vs 53.4% YoY; improved sequentially from 51.4% in Q2.
Op. LeverageOperating expenses grew 5% vs 10% revenue growth, showing positive leverage.
Pricing PowerTransitioning IFC to kit model offers more attractive gross margins despite lower price.
Vol vs PriceVolume-led; North American platelet kits and doses increased 5% year-over-year.
Segment GrowthIFC sales volume increased 7% sequentially; 90% of IFC now kit-based.
New ClientsDeepened Blood Centers of America (BCA) relationship; Grady Memorial Hospital adoption.
Capex & DebtGenerated $3M cash flow; $57.1M cash balance; refreshed shelf registration statement.
RegulatoryCE Mark delayed to late 2027; FDA requested incremental data for INT200.
CommentaryFocusing on establishing Intercept as global standard of care via clinical evidence.
New LaunchesPhase III Redis top-line results; INT200 illuminator international rollout continuing.

Growth

Product revenue rose 10% to $57.7M; North America up 12%, EMEA up 5%.

Outlook

Reaffirmed 2026 revenue guidance of $229M-$231M; CE Mark clearance now expected late 2027.

Risks

Management used vague language regarding specific FDA data requirements for INT200, delaying approval visibility.

Source

The company's earnings call, NASDAQ: CERS, and its 8-K filed with the SEC. Summary written with AI assistance from the call.

Read the 8-K ↗

Cerus Corp: key numbers

Share price
$1.86Close, Nov 16
Market cap
$376M
Shares outstanding
201.95MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Cerus Corp

All →
4:20 PM ET 10-Q
Financial Results ▶ Call

Cerus Q3 2026 Results: Net Loss of $550K, Loss Widens

For the quarter ended September 30, 2026, Cerus Corporation reported product revenue of $57.7 million, a 9.5% increase over the prior year, and achieved a narrow net loss of $0.6 million. The company significantly reduced its nine-month net loss from $13.5 million in 2025 to $5.2 million in 2026, driven by higher gross profits and lower research and development expenses.

Key figure
Net loss $550K
4:08 PM ET 8-K
Financial Results

Cerus Financial Results

Cerus Corporation reported Q3 2026 total revenue of $64.0 million, driven by 10% year-over-year growth in product revenue to $57.7 million. The company also announced positive topline Phase 3 results for its INTERCEPT Blood System for red blood cells and generated $3.0 million in operating cash flow during the quarter.

Term
Q3 2026

“Our solid performance in Q3 builds upon a strong first half of 2026 and increases our confidence as we approach year-end. Continued growth from our IFC business, core platelet franchise and international INT 200 rollout strengthens our foundation as we work to establish INTERCEPT as the global standard of care.”

Vivek Jayaraman, Cerus’s president and chief executive officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.